CDMO Andelyn Biosciences entered into a license agreement with the Broad Institute to expand its AAV Curator™ platform offering to include MyoAAV plasmids. Developed by researchers at the Broad Institute of MIT and Harvard, this new family of plasmids produce adeno-associated viruses (AAVs) that are ten times more efficient in reaching muscle tissue than wild-type vectors, while also de-targeting the liver, according to Matt Niloff, chief commercial officer of Andelyn. With more precise targeting of muscle tissue, research shows MyoAAV-delivered therapies may require lower dosing, he adds.
The allows Andelyn to use the MyoAAV plasmids to perform research and development services for its clients who are developing gene therapies to screen potential candidates at Andelyn and to perform scaleup and preclinical development work in preparation for IND-enabling studies. The agreement also permits Andelyn to sublicense the MyoAAV plasmids to its clients for internal research purposes.
“Our license from the Broad Institute furthers our goal of providing the industry access to critical tools and capabilities that facilitate the development of innovative therapies to bring more treatments to more patients,” adds Niloff. “With access to the increased specificity of MyoAAVs, our clients now have the opportunity to maximize efficiency in their gene therapy processes and drive down the cost per patient.”
